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Abstract
Definitions of basal-like breast cancer phenotype vary, and microarray-based expression profiling analysis remains the 
gold standard for the identification of these tumors. Immunohistochemical identification of basal-like carcinomas is 
hindered with a fact, that on microarray level not all of them express basal-type cytokeratin 5/6, 14 and 17. We 
compared expression of cytokeratin 5, 14 and 17 in 115 patients with operable breast cancer estimated by real-time RT-
PCR and immunohistochemistry.
Despite the method of dichotomization and statistical analysis, there were cases with discordant results comparing 
immunohistochemistry and RT-PCR analysis. For dichotomisation based on quartiles and ROC, 14% of cases were 
negative on immunohistochemical examination for CK5/6, but presented high CK5 mRNA levels. There were also 48-
55% cases, which were CK5/6-immunopositive, but were negative by mRNA examination. Similar discordances were 
observed for CK14 and CK17.
Basal keratin mRNAs did not correlate with ER mRNA levels, while immunohistochemistry produced significant 
relationship with ER status.
Our observation suggest that both method may produce different results in a small proportion of cases. Discordance 
between immunohistochemistry and RT-PCR may confound attempts to establish a simple methods for identification 
of basal-like tumors.
Introduction
Heterogeneity of breast cancer at the molecular level was
supported by data from cDNA microarrays [1,2]. Tumors
lacking ER form three groups: a basal-like subtype,
HER2-positive subtype, and a normal breast-like subtype.
Basal-like subtype is characterized by multigenetic signa-
ture, usually with high expression of high molecular
weight cytokeratins normally expressed in basal myoepi-
thelial cells: keratin 5 (CK5), 14 (CK14) and keratin 17
(CK17) [1,2]. They usually express vimentin and p-cad-
herin, and more than 60% of them also express epidermal
growth factor receptor (EGFR) [3,4].
A great interest in basal like-cancers produced attempts
to determine basal-like tumors by the use of a much more
easier technique such as immunohistochemistry. Unfor-
tunately, both methods -- oligonucleotide microarrays
and immunohistochemistry - do not produce identical
results. In the study by Nielsen and al., immunohis-
tochemical panel for basal-like cancers was defined as
lack of ER and HER2 expression and positivity for CK5/6
or EGFR [5]. Unfortunately, this panel still presented only
76% sensitivity for basal-like tumors derived from a
microarray study.
Another attempt to simplify the determination of basal-
like tumors was regarding them as synonymous with "tri-
ple negative tumors", regarded as lack of ER, PGR and
HER2 [6]. But according to comparative studies, as much
as 15-54% of basal-like tumors defined on mRNA level,
still express at least one of these markers [4,5,7-9].
Quantitative real-time RT-PCR technology provides a
precise assessment of even small changes in gene expres-
sion. In this aspect, real-time RT-PCR is a much more
sensitive assay when compared with oligonucleotide
microarray and could be considered as a referential
method [10]. This raises the question whether microar-
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ray-based classification of breast tumors could be recon-
structed or even improved by the use of data from the
quantification of expression of selected genes assessed by
real-time RT-PCR. Recently, there have been published
some data supporting this thesis [11].
In a previous study, we have compared ER expression
estimated by RT-PCR and by a routine immunostaining,
and have validated which method might be more reliable
for the molecular subtyping in relation with basal-type
keratins and HER2 genes expression [12]. Both methods
produced discordant results in a proportion of cases, and
lack of prognostic relevance of ER-mRNA level has been
demonstrated, whereas the assessment by immunostain-
ing has been related to clinical outcome. Also expression
of basal keratins and HER2 genes significantly differed
between ER-positive and ER-negative tumors divided on
the basis of immunostaining, but not by mRNA level.
Whereas immunostaining results are specific for tumor
cells, mRNA for the RT-PCR analysis could originate not
only from cancer cells but also from normal breast epi-
thelium, myoepithelial and stromal cells. Furthermore,
due to post-transcriptional and post-translational mecha-
nisms, the amount of detected mRNA not always directly
reflects protein level.
On the contrary, qRT-PCR may produce similar results
of ER expression as obtained by immunohistochemistry,
but only with a very stringent and quality controlled sys-
tems [13]. Besides, immunohistochemistry still remains
the gold standard for estimation of ER status in breast
cancer.
Although, as stated by Reis-Filho and Tutt, "from a sci-
entific perspective, microarray-based expression profiling
analysis remains the gold standard for the identification
of basal breast cancers", stringent analysis of profiles dis-
closes that in basal-like cases there is low expression of
basal cytokeratins in a few cases [2-4]. Similarly, in some
luminal-type tumors there are cases with high expression
of CK5 or CK14 [2,3]. As mRNA for basal-type cytokera-
tins may originate from myoepithelial cells forming nor-
mal breast tissue intermixed with cancer cell, or the
number of cancer cells even presenting these cytokeratins
may be to sparse -- in both situations false results may be
obtained.
The aim of this retrospective study was to compare
basal-cell-type cytokeratin expression estimated by real-
time RT-PCR and by a routine immunostaining.
Patients and Methods
Tumor specimens and study patients
Specimens of primary tumors were consecutively
obtained from 115 women with operable invasive ductal
carcinomas not otherwise specified (NOS) at a time of
routine surgery at the Oncology Department of Coperni-
cus Memorial Hospital in Lodz, Poland, between 1998
and 2001. In all cases, surgical procedure was a radical
mastectomy with axillary lymph node dissection. Serial
sections of the tumor were obtained from archived paraf-
fin embedded tissue blocks. The primary pathologic diag-
nosis was confirmed in H&E staining. Subsequent slides
were stained for ER and HER2. For further mRNA analy-
sis, fresh tumor specimens were frozen immediately after
excision at -80°C. Patient characteristics are presented in
table 1.
Immunohistochemistry and scoring
Paraffin embedded sections were routinely processed.
Slides for immunostaining for ER (Dako), CK14 and
CK17 (both Novocastra) were pretreated with citrate buf-
fer in a microwave oven. CK5/6 antibody from Dako was
applied following autoclaving with high pH buffer. Anti-
body dilutions were as follows: ER - 1:35, CK5/6 - 1:100,
CK14 -- 1:20, CK17 - 1:40. All following procedures were
done according to standard protocols with EnVision+
System HRP (Dako). ER nuclear staining scoring was
done using the method described by McCarty et al. [14].
Tumors were considered as being positive for ER if Histo-
score was above 100. The results of basal keratin mem-
branous staining were classified as follows: negative - no
staining seen in invasive cancer cells, positive -- weak or
strong staining seen in invasive cancer cells. HER2
expression was examined with the commercially available
Herceptest kit from Dako and score +3 denoted HER2-
positive tumors.
Real-time RT-PCR analysis
Tumor samples were stored at -80°C until mRNA extrac-
tion using TRIzol®  Reagent (Invitrogen Corporation,
USA). Synthesis of cDNA was performed from 10 μg of
total mRNA at a total volume of 70 μl using ImProm-II™
(Promega Corporation, USA) reverse transcriptase. Next,
cDNA samples were diluted with sterile deionized water
to a total volume of 140 μl. Volumes of 2 μl (correspond-
ing to 0, 14 μg of total mRNA) were used for PCR. Real-
time RT-PCR was performed using Rotor-Gene™ 3000
(Corbett Research). Sequences of primers used, annealing
and detection temperatures are presented in Table 2. All
primers were designed to not amplify genomic DNA
(usually one is positioned on exon-exon junction). Primer
pairs were blasted against human genome ref_assembly
37.1 using electronic PCR on NCBI Genome Database
and showed no genomic or pseudogenes PCR products.
All reactions were made in triplicate. Detection of PCR
products was performed with SYBR™ green I using qPCR
Core kit for SYBR™ green I (Eurogentec, Belgium).
Expression levels of target genes were normalized using
f o u r  h o u s e k e e p i n g  g e n e s :  B 2  M ,  H 3 F 3 A ,  R P L P 0 ,  a n d
RPS17. Relative gene expression was calculated with the
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Statistical analysis
Mann-Whitney U test was employed to evaluate signifi-
cance of differences in mRNA level between groups.
Dichotomized values of mRNA level were compared with
immunohistochemistry using the matched pairs Liddell's
exact test and Scott's π test. Data were analyzed with
respect to sensitivity and specificity derived from the
receiver operating characteristic (ROC) and immunohis-
tochemistry was regarded as a referential test. Kendall's
rank correlation (τ) was used to test the strength of an
association between expression of genes. Pearson's χ2 test
or Fisher's exact test were used to test for contingency
between dichotomized values of basal keratin expression
(negative and positive) and values of other histopatholog-
ical parameters. All results were considered statistically
significant when two-sided p was less than 0.05.
Results
In 73 cases (63,5%) identified immunohistochemically as
being CK5/6-negative, mean CK5 gene expression was
significantly lower, than in cases classified by immunos-
taining as being CK5/6-positive (table 3, p = 0,001). Simi-
lar results were observed for CK14 and CK17 (p = 0,007
and p < 0,001, respectively; table 3).
The comparisons between dichotomized values of
CK5-mRNA level and CK5/6 immunohistochemical sta-
tus demonstrated, that despite the method of dichotomi-
zation and statistical analysis, there were cases with
discordant results comparing immunohistochemistry
and RT-PCR analysis. For two methods of dichotomisa-
tion (quartiles and based on ROC; the ROC curve analy-
sis was performed assuming that immunostaining was a
reference test), there were still 48-55% cases, which were
CK5/6-immunopositive, but were negative by mRNA
examination. Similarly, 14% of cases were negative on
immunohistochemical examination, but presented high
mRNA levels. Similar discordances were observed for
CK14 and CK17.
Highly significant, moderate, positive correlations
between mRNA levels of CK5 and CK14 (τ = 0.40, 95%CI
0.29-0.51, p < 0,001), between CK5 and CK17 (τ = 0.51,
95%CI 0.40-0.62, p < 0,001), and between CK14 and
CK17 (τ = 0.36, 95%CI 0.25-0.47, p < 0,001) were
observed.
When samples were divided in respect of basal keratins
status on the basis of immunohistochemistry, significant
difference in ER-mRNA level between positive and nega-
tive ones was found. We also observed significant rela-
tionship between basal keratin expression and ER status,
when both were estimated by immunohistochemistry.
Tumours positive for these keratins usually lacked ER
receptor (table 4, 5). To the contrary, basal keratin
mRNAs did not correlate with ER mRNA levels. When a
group of 53 cases samples positive for basal keratins on
Table 1: Patient characteristics
Factor Number of patients
Number of patients 115
Age (years)
≤ 50 39 (33,9%)
> 05 76 (66,1%)
Tumour
T1 33 (28,7%)
T2-4 82 (71,3%)
Nodal status
Positive 56 (48,7%)
Negative 59 (51,3%)
Grade
G1-2 63 (54,8%)
G3 52 (45,2%)
ER status
Positive 60 (52,2%)
Negative 55 (47,8%)
CK5/6 status (IHC)
Positive 42 (36,5%)
Negative 73 (63,5%)
CK14 status (IHC)*
Positive 16 (14,0%)
Negative 98 (86,0%)
CK17 status (IHC)
Positive 29 (25,2%)
Negative 86 (74,8%)
Adjuvant treatment
Chemotherapy 66 (57,4%)
Hormonotherapy 82 (71,3%)
Radiotherapy 21 (18,3%)
Missing data 8 (7,0%)
* In one sample assessment was not possible due to technical 
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Table 2: Real-time RT-PCR primers and reaction conditions
Gene primers (5'-3')
Forward
Reverse
Annealing temperature (°C) Detection temperature (°C) PCR product size (base 
pairs)
Beta-2-microglobulin (B2M)
TGAGTGCTGTCTCCATGTTTGA
TCTGCTCCCCACCTCTAAGTTG
50 81 88
H3 histone, family 3A (H3F3A)
AGGACTTTAAAAGATCTGCGCTTCCAGAG
ACCAGATAGGCCTCACTTGCCTCCTGC
65 72 76
Ribosomal phosphoprotein (RPLP0)
ACGGATTACACCTTCCCACTTGCTAAAAGGTC
AGCCACAAAGGCAGATGGATCAGCCAAG
65 72 69
Ribosomal protein S17 (RPS17)
ACCCCAATGTCAAGGAGATCAAGGTCCTG
TCGGCAGCCAGCTCGTGAGTAATG
64 72 87
Estrogen receptor 1 (ER)
ATCTCGGTTCCGCATGATGAATCTGC
TGCTGGACAGAAATGTGTACACTCCAGA
65 72 98
Keratin 5 (CK5)
ATCGCCACTTACCGCAAGCTGCTGGAGGG
AAACACTGCTTGTGACAACAGAG
65 72 102
Keratin 17 (CK17)
ATGTGAAGACGCGGCTGGAGCAGGA
ACCTGACGGGTGGTCACCGGTTC
65 72 109
Keratin 14 (CK14)
TTTGGCGGCTGGAGGAGGTCACA
ATCGCCACCTACCGCCGCCTG
65 72 109
the basis of mRNA assessment was selected, there was no
significant difference in mean ER-mRNA level when
compared with negative ones. Similar analyses were per-
formed assuming other cut-off points in the process of
dichotomization of basal keratin mRNAs: < median vs ≥
median, Q1-3 vs Q4, and log2 ratio (<0.65 vs ≥ 0.65).
There were no significant differences in ER mRNA level
regardless of the cut-off point selected (p value: 0,752,
0,331, and 0,059, respectively). In the last analysis, when
log2 ratio (<0.65 vs ≥ 0.65) cut-off point was selected,
only 5 cases were classified as being negative for basal
keratin mRNA, whereas remaining 110 cases were classi-
fied as being positive.
Discussion
Basal-like breast cancers recently have raised a great
interest not only regarding clinical differences, but also in
relation with new therapeutic possibilities. The vast
majority of BRCA1 mutation-related breast tumors rep-
resent basal-like subtype. Moreover, Turner et al. have
recently reported the high prevalence of BRCA1 down-
regulation in sporadic basal-like breast cancer [15]. There
are some promising data that platinum-based chemo-
therapy may be more effective in patients with BRCA-1
germline mutations or in "triple-negative" breast cancer
[16,17]. These observations may emphasize the impor-
tance of an easy and simple determination of basal-like
phenotype.Kordek et al. Journal of Experimental & Clinical Cancer Research 2010, 29:39
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A microarray analysis is a very elegant and sophisti-
cated method, but for individual genes it is equivalent to
estimation of mRNA level by the use of RT-PCR. Both
methods have one important weakness -- the assessment
of gene expression is based on total mRNA presented in
the examined tissue, not only in cancer cells - and this
weakness may produce false results in a proportion of
cases. In our study, in a comparison of immunohis-
tochemistry and RT-PCR, regardless of the method of
dichotomization and statistical analysis used, there were
cases with discordant results. For each cytokeratin, there
were cases which were regarded as being positive by one
method, and negative by the other one. Fourteen percent
of cases were negative for CK5/6 as assessed by an immu-
nohistochemical examination, but presented high CK5
mRNA levels. Similar discordances were also observed
for CK14 and CK17. This observation suggests that in
some cases high levels of basal keratin mRNA may origi-
nate not from cancer cells but possibly also from preexist-
ing normal myoepithelial cells. Furthermore, due to the
post-transcriptional and post-translational mechanisms,
the amount of detected mRNA not always directly
reflects protein level. The same applies to oligonucleotide
microarrays.
Similar differences were observed in an opposite direc-
tion - some cases which were positive by immunohis-
tochemistry were regarded as being negative by real-time
RT-PCR. For CK5/6, there is a theoretical possibility that
Table 3: mRNA of respective basal keratin genes depending on their status assessed by immunohistochemistry
Status by IHC mRNA level p value
Median; range Mean ± SD
CK5/6 negative 24.69; 0.00-4495.16 206.67 ± 727.20 0,001
CK5/6 positive 192.92; 0.00-3066.48 424.48 ± 731.51
CK14 negative 67.50; 0.00-6615.26 209.45 ± 684.34 0,007
CK14 positive 250.52; 0.00-10569.08 1480.20 ± 2958.21
CK17 negative 0.15; 0.00-22.22 0.69 ± 2.47 <0,001
CK17 positive 1.15; 0.01-26.44 3.11 ± 5.49
Table 4: Relations between basal keratins expression and ER status assessed by immunohistochemistry
Basal keratin ER p value
Negative Positive
CK5/6
Negative 20 53 <0,001
Positive 35 7
CK14
Negative 39 59 <0,001
Positive 15 1
CK17
Negative 30 56 <0,001
Positive 25 4
The table contains numbers of patientsKordek et al. Journal of Experimental & Clinical Cancer Research 2010, 29:39
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cells may express only CK6 and not CK5, but the same
observation was made for CK14 and CK17. Possibly, the
amount of immunopositive cancer cells in the sample was
too small to give positive results by RT-PCR when mRNA
levels were dichotomized.
Moreover, for both types of discordances, it may be one
universal explanation: because of the heteregeneity of the
tumor, tissue examined by immunohistochemistry was
not exactly the same tissue which was examined by real-
time RT-PCR.
We have found that basal keratin mRNA does not
inversely correlate with ER mRNA level. This is an inter-
esting observation, as in the published studies with the
use of microarray technology such correlation is clear [1-
3]. But when our samples were divided regarding basal
keratin status on the basis of immunohistochemistry
results, we observed significant relationship with ER sta-
tus, estimated both by RT-PCR and by immunohis-
tochemistry. It shows that immunohistochemistry may be
a better method than RT-PCR in rendering a biological
difference of basal-like tumors.
Studies that were conducted to establish which immu-
nohistochemical markers were helpful for the best defini-
tion of basal-like tumors gave different results [18-22].
Rakha et al. suggested that only expression of basal-type
cy t o k e r a t i n s  ( C K 5 / 6  a n d  C K 1 4 )  s h o u l d  b e  i n c l u d e d  i n
such definition [21]. In their study, no other marker was
related with worse prognosis. More recently, some
a u t h o r s  h a v e  c l a i m e d  t h a t  E G F R  e x p r e s s i o n  s h o u l d  b e
added to the panel, and even in the absence of basal-
cytokeratins, ER- and HER2-negative tumors presenting
EGFR s hould be r egar ded as basal-type ones [5,20,21].
Nielsen at al. determined that 13 of 21 basal-type cancers
from microarray study were CK5/6-positive by immuno-
histochemistry, 12 of them were EGFR-positive, and 6 of
them were c-KIT-positive [5]. However, these authors
regarded as a positive case even the weakest reaction.
They also found that EGFR-positivity was correlated with
basal-type gene expression and was related with worse
survival; the same applied to CK5/6-positive tumors.
This observation is encouraging but it is still questionable
that EGFR-positive tumors should be named as "basal-
type". Fulford et al. found a good correlation with clinical
outcome when as the "basal-like" tumors were only
regarded the cases with the presence of keratin 14 [22].
Summarizing, we have demonstrated a discordance
between real-time RT-PCR and immunohistochemistry
in assessing basal-type cytokeratin status. This observa-
tion gives another difficulty in establishing an easy and
s i m p l e  m e t h o d  o f  i d e n t i f i c a t i o n  o f  t u m o r s  t h a t  h a v e  a
basal-like signature in microarray analysis.
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